New CAR-T Drug Induces Durable Remissions in ALL, Published Data Show

Published Date: 02 Dec 2024

Results of FELIX study supported obecabtagene autoleucel's recent FDA approval

Read Full News

Latest News

Single-dose radiation before surgery can eradicate breast cancer

A single, targeted high dose of radiation delivered before other treatments could completely eradicate tumors in most women with early-stage, operable hormone-positive breast cancer, according to a study led by UT Southwestern ...

Why palliative care goes hand in hand with treatment for people with cancer: Q&A

For many people with cancer and other serious diseases, palliative care is an important element of their journey.

Q&A: Odds of surviving cancer drop drastically when credit score dips

While past studies have explored how cancer patients' financial health influenced their risk of mortality, new research digs in deeper by zeroing in on objective data: credit scores.

Traces of bacteria inside brain tumors may affect tumor behavior

Researchers at The University of Texas MD Anderson Cancer Center have uncovered unexpected traces of bacteria within brain tumors. This discovery offers new insights into the environment in which brain tumors grow and sets ...

Cancer care crowdfunding increasingly common, but rarely successful

A growing number of desperate cancer survivors are turning to crowdfunding to help pay for their treatment and living expenses, a new study says.

Food insecurity linked to tumor growth in pediatric neuroblastoma

Neuroblastoma remains one of the deadliest childhood malignancies, accounting for a disproportionate number of pediatric cancer deaths worldwide.

Todays Updates

CAR-T Therapy KYV-101 Achieves Durable Response in Phase 2/3 KYSA-6 Trial of Myasthenia Gravis Marco Meglio

KYV-101 shows promising efficacy in treating generalized myasthenia gravis, offering hope for durable remission through innovative CAR T-cell therapy.

Reimagining Neuroscience Trials: Precision, Partnership, and Progress Marco Meglio, Daniel Mikol, MD, PhD

Daniel Mikol, MD, PhD, vice president of neuroscience development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.

MIL62 Shows Increased Remission and Reduced Relapse Versus Cyclosporine A in MN

MIL62 Shows Increased Remission and Reduced Relapse Versus Cyclosporine A in MN

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

Todays Updates

CAR-T Therapy KYV-101 Achieves Durable Response in Phase 2/3 KYSA-6 Trial of Myasthenia Gravis Marco Meglio

KYV-101 shows promising efficacy in treating generalized myasthenia gravis, offering hope for durable remission through innovative CAR T-cell therapy.

Reimagining Neuroscience Trials: Precision, Partnership, and Progress Marco Meglio, Daniel Mikol, MD, PhD

Daniel Mikol, MD, PhD, vice president of neuroscience development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.

MIL62 Shows Increased Remission and Reduced Relapse Versus Cyclosporine A in MN

MIL62 Shows Increased Remission and Reduced Relapse Versus Cyclosporine A in MN

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

Latest News

A single, targeted high dose of radiation delivered before other treatments could completely eradicate tumors in most women with early-stage, operable hormone-positive breast cancer, according to a study led by UT Southwestern ...

For many people with cancer and other serious diseases, palliative care is an important element of their journey.

While past studies have explored how cancer patients' financial health influenced their risk of mortality, new research digs in deeper by zeroing in on objective data: credit scores.

Researchers at The University of Texas MD Anderson Cancer Center have uncovered unexpected traces of bacteria within brain tumors. This discovery offers new insights into the environment in which brain tumors grow and sets ...

A growing number of desperate cancer survivors are turning to crowdfunding to help pay for their treatment and living expenses, a new study says.

Neuroblastoma remains one of the deadliest childhood malignancies, accounting for a disproportionate number of pediatric cancer deaths worldwide.

News All Time

How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace

Bacteria are rapidly emerging as a new class of "living medicines" used to kill cancer cells.

Study shows supervised exercise improves strength, physical performance in patients with advanced breast cancer

Aerobic and resistance exercise can significantly improve physical performance in patients living with metastatic breast cancer, according to new results presented at the Advanced Breast Cancer Eighth International Consensus ...

Combination treatment may help cut lifelong ibrutinib for chronic lymphocytic leukemia patients

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the Western Hemisphere, affecting approximately 200,000 people in the United States.

Advanced breast cancer patients living longer thanks to improvements in treatment and care

People diagnosed with advanced breast cancer in 2025 can expect to live for an extra six or seven months, compared to the average survival time for patients diagnosed in 2011, according to a major study of patient data in ...

Radiotherapy after mastectomy can be avoided, study finds

Radiotherapy can be safely omitted as a treatment for many breast cancer patients who have had a mastectomy and are taking anti-cancer drugs, a study shows.

Data-driven risk stratification guides childhood brain tumor treatment, reducing side effects

By analyzing data from three clinical trials treating children with the brain tumor medulloblastoma, scientists at St. Jude Children's Research Hospital have designed an approach to safely reduce therapy, thereby lowering ...

Sustained reduction found in prostate cancer mortality with prostate-specific antigen screening

A European study has demonstrated a sustained long-term reduction in prostate cancer mortality through prostate-specific antigen (PSA) screening. However, the findings also highlight the issue of overdiagnosis, or the detection ...

How access to specialized cancer centers affects glioblastoma outcomes

Glioblastoma is one of the most aggressive and complex brain cancers. It grows quickly, resists standard treatments, and often leaves patients and their families searching for every possible option.

Is global cancer care losing its human touch?

A new Lancet Oncology Commission highlights a growing "human crisis" in cancer care. Despite advances in treatment and increased survival rates, many patients worldwide are not receiving the compassionate, holistic support ...

Indoor hydroponic gardening can improve mental health and quality of life for cancer patients

Indoor hydroponic gardening—a method of growing plants using nutrient-rich water instead of soil—could help cancer patients develop better mental health, eat a healthier diet and enjoy a better overall quality of life.

Clinical trial sees dramatic results using radiation to treat breast cancer

Almost immediately after Theresa Greco was diagnosed with breast cancer in March, doctors asked her whether she wanted to participate in a clinical trial. The trial would do high-powered radiation targeted at her tumor prior ...

Dual-action mRNA vaccine takes aim at aggressive skin cancer

Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting the protein essential to tumor cell growth and by adding a key signal to boost the immune system response. ...

For incarcerated people, study shows gaps exist in quality of cancer care

In the United States, the incarcerated population is aging. About 15% of incarcerated adults, or approximately 175,000 people, are now 55 years or older.

Molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic target

Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and most comprehensive molecular analysis of renal medullary carcinoma (RMC), a rare and aggressive ...

FDA approves Blenrep for relapsed or refractory multiple myeloma

The U.S. Food and Drug Administration approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.

Radiation therapy for patients with breast cancer

Radiation therapy is a common component of breast cancer treatment for patients. The high-powered beams of intense energy kill cancer cells and reduce the risk of the cancer recurring.

Recommended News For You

New Zealand and Australian breast cancer rates among the highest in the world, global study finds

According to the Lancet, having cancer and VTE at the same time increases mortality risk.

Sydney researchers identify new tools to improve cancer diagnosis and treatment.

Adaptive SABR-Used Hypofractionated Chemoradiation Showed Good Results in NSCLC.

Earlier Info on Financial Stress; Obesity and Second Cancers; Carcinogenic Condoms?

Cancer deaths expected to rise to over 18 million in 2050, nearly 75% more than in 2024

Using AI, one can find cancer risk factors.

Recommended Articles For You

Chondroma: What it is and How it Affects Your Health  

Mastering Breast Cancer Care in 2025: Diagnosis, Treatment, Education, and Innovation 

Cancer Trials 2025: Vaccines, Metabolic Targets, and the Microbiome in Oncology 

Future of Chemotherapy: New Advances, Treatments & Survival Rates Transforming Cancer Care 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA Greenlights First Engineered Cell Therapy for a Solid Tumor

2.

New CAR-T Drug Induces Durable Remissions in ALL, Published Data Show

3.

The FDA Approves the New Frontline Aggressive ALL Regimen.

4.

Childhood brain tumors develop early in highly specialized nerve cells, research reveals

5.

Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.

1.

Decoding Granular Cell Tumor: What You Need to Know

2.

Omega-3 Fatty Acids as Molecular Adjuvants Against Chemoresistance in Breast Cancer

3.

Mechanistic Insights into Abraxane, Verzenio, and the Management of Chemotherapy-Induced Tachycardia

4.

Unlocking the Power of Cryoprecipitate: A Comprehensive Guide

5.

Frontiers in Cancer Therapeutics: U.S. Oncology Trials and Drug Discovery Trends

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II

2.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV

3.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

4.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II

5.

Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot